Babl Franz E, Mackay Mark T, Borland Meredith L, Herd David W, Kochar Amit, Hort Jason, Rao Arjun, Cheek John A, Furyk Jeremy, Barrow Lisa, George Shane, Zhang Michael, Gardiner Kaya, Lee Katherine J, Davidson Andrew, Berkowitz Robert, Sullivan Frank, Porrello Emily, Dalziel Kim Marie, Anderson Vicki, Oakley Ed, Hopper Sandy, Williams Fiona, Wilson Catherine, Williams Amanda, Dalziel Stuart R
Department of Emergency Medicine, Royal Children's Hospital, Flemington Rd, Parkville, VIC, 3052, Australia.
Murdoch Children's Research Institute, Parkville, Victoria, Australia.
BMC Pediatr. 2017 Feb 13;17(1):53. doi: 10.1186/s12887-016-0702-y.
Bell's palsy or acute idiopathic lower motor neurone facial paralysis is characterized by sudden onset paralysis or weakness of the muscles to one side of the face controlled by the facial nerve. While there is high level evidence in adults demonstrating an improvement in the rate of complete recovery of facial nerve function when treated with steroids compared with placebo, similar high level studies on the use of steroids in Bell's palsy in children are not available. The aim of this study is to assess the utility of steroids in Bell's palsy in children in a randomised placebo-controlled trial.
METHODS/DESIGN: We are conducting a randomised, triple-blinded, placebo controlled trial of the use of prednisolone to improve recovery from Bell's palsy at 1 month. Study sites are 10 hospitals within the Australian and New Zealand PREDICT (Paediatric Research in Emergency Departments International Collaborative) research network. 540 participants will be enrolled. To be eligible patients need to be aged 6 months to < 18 years and present within 72 hours of onset of clinician diagnosed Bell's palsy to one of the participating hospital emergency departments. Patients will be excluded in case of current use of or contraindications to steroids or if there is an alternative diagnosis. Participants will receive either prednisolone 1 mg/kg/day to a maximum of 50 mg/day or taste matched placebo for 10 days. The primary outcome is complete recovery by House-Brackmann scale at 1 month. Secondary outcomes include assessment of recovery using the Sunnybrook scale, the emotional and functional wellbeing of the participants using the Pediatric Quality of Life Inventory and Child Health Utility 9D Scale, pain using Faces Pain Scale Revised or visual analogue scales, synkinesis using a synkinesis assessment questionnaire and health utilisation costs at 1, 3 and 6 months. Participants will be tracked to 12 months if not recovered earlier. Data analysis will be by intention to treat with primary outcome presented as differences in proportions and an odds ratio adjusted for site and age.
This large multicenter randomised trial will allow the definitive assessment of the efficacy of prednisolone compared with placebo in the treatment of Bell's palsy in children.
The study is registered with the Australian New Zealand Clinical Trials Registry ACTRN12615000563561 (1 June 2015).
贝尔麻痹或急性特发性下运动神经元性面瘫的特征是由面神经控制的一侧面部肌肉突然出现麻痹或无力。虽然在成人中有高水平证据表明,与安慰剂相比,使用类固醇治疗时面神经功能的完全恢复率有所提高,但关于在儿童贝尔麻痹中使用类固醇的类似高水平研究尚无。本研究的目的是在一项随机安慰剂对照试验中评估类固醇在儿童贝尔麻痹中的效用。
方法/设计:我们正在进行一项随机、三盲、安慰剂对照试验,以研究泼尼松龙对改善贝尔麻痹1个月恢复情况的作用。研究地点为澳大利亚和新西兰PREDICT(国际急诊科儿科研究协作组)研究网络内的10家医院。将招募540名参与者。符合条件的患者年龄需在6个月至18岁之间,且在临床诊断为贝尔麻痹发作后72小时内就诊于其中一家参与研究的医院急诊科。如果患者目前正在使用类固醇或有类固醇使用禁忌证,或者存在其他诊断,则将被排除。参与者将接受泼尼松龙1毫克/千克/天(最大剂量50毫克/天)或口味匹配的安慰剂治疗10天。主要结局是1个月时根据House-Brackmann量表达到完全恢复。次要结局包括使用Sunnybrook量表评估恢复情况、使用儿童生活质量量表和儿童健康效用9D量表评估参与者的情绪和功能健康状况、使用面部疼痛量表修订版或视觉模拟量表评估疼痛、使用联带运动评估问卷评估联带运动以及评估1、3和6个月时的医疗利用成本。如果参与者未提前康复,将对其进行追踪至12个月。数据分析将采用意向性分析,主要结局以比例差异和根据研究地点及年龄调整的优势比呈现。
这项大型多中心随机试验将能够明确评估泼尼松龙与安慰剂相比在治疗儿童贝尔麻痹方面的疗效。
该研究已在澳大利亚新西兰临床试验注册中心注册,注册号为ACTRN12615000563561(2015年6月1日)。